Executive Summary
Azoth Analytics has released a research report titled "Metabolic Syndrome Market (2023 Edition)" which provides a complete analysis of the global Metabolic Syndrome industry in terms of market segmentation By Indication (Insulin Resistance Syndrome, Hypercholesterolemia, Obesity Syndrome, Nonalcoholic steatohepatitis, Other Indications), By Molecule Type (Small Molecule, Protein, RNA/DNA, Other Molecules) and By Route of Administration (Oral, Subcutaneous, Other ROA) for the historical period of 2018-2022, the estimated year 2023 and the forecast period of 2024-2028.
The research study is global in nature and covers a detailed analysis of the market in the Americas (U.S., Canada, Rest of Americas), Europe (France, U.K, Italy, Spain, Germany, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), and the Middle East and Africa. Additionally, the research report presents data including market size, yearly growth & potential analysis, the competitive study of market players, investment opportunities, demand for future forecast, and so on.
The research study also assesses market growth indicators, restraints, supply and demand risk, and other important statistics, as well as a full assessment of current and future market trends that are relevant to the market evolution.
The Global Metabolic Syndrome Market is expected to generate USD 28.9 billion by the end of 2028, up from USD 22.5 billion in 2021. Metabolic syndrome is a complicated disorder characterized by a group of linked metabolic abnormalities that raise the risk of cardiovascular disease, type 2 diabetes, and other major health problems. It is a global health issue with significant public health implications. Central obesity, high blood pressure, dyslipidemia (abnormal lipid profile), and reduced metabolism of glucose are important components of metabolic syndrome. During the forecast period, 2024-2028, the Global Metabolic Syndrome market is expected to expand at a CAGR of 46.30%.
In addition, as the healthcare sector moves toward a more preventive and customized approach, there is a greater emphasis on early detection and management to reduce the risk of metabolic syndrome-related challenges. This pattern is likely to fuel demand for diagnostic tests, treatment options, and digital health solutions.
Companies are working on creating novel drugs that address many aspects of metabolic syndrome at the same time. This strategy seeks to enhance patient outcomes while reducing the need for multiple drugs. Furthermore, technological advances such as wearable gadgets and mobile applications have evolved to assist individuals in monitoring their health metrics and successfully managing their condition.
Among the Indication type, Insulin Resistance Syndrome holds the maximum share in the market. The global market for therapeutics of Insulin resistance Metabolic Syndrome is expected to grow in the coming years, driven by the increasing prevalence of Diabetes.
This study also provides a competitive landscape of the industry and profiles leading players in the Global Metabolic Syndrome Market including Novo Nordisk, Eli Lilly and Company, Takeda Pharmaceutical, Sanofi, AstraZeneca, Amgen, Merck Co., Inc., Johnson & Johnson, Pfizer, and Abbott. The company profiling includes critical information such as a business overview, Drug Molecule type and other products, key financials, and recent events and developments. Overall, the report provides a detailed overview of the Global Metabolic Syndrome Market, which will assist industry consultants, equipment manufacturers, existing players looking for expansion opportunities, new players looking for opportunities, and other stakeholders in aligning their market-centric strategies with current and expected future trends.
Scope of the Report:
• The report analyses the Metabolic Syndrome Market by Value (USD Million).
• The report presents the analysis of Metabolic Syndrome market for the historical period of 2018-2022, the estimated year 2023 and the forecast period of 2024-2028.
• The report analyses the Metabolic Syndrome Market by Indication (Insulin Resistance Syndrome, Hypercholesterolemia, Obesity Syndrome, Nonalcoholic steatohepatitis, Other Indications).
• The report analyses the Metabolic Syndrome Market by Molecule Type (Small Molecule, Protein, RNA/DNA, Other Molecules).
• The report analyses the Metabolic Syndrome Market by Route of Administration (Oral, Subcutaneous, Other ROA).
• The Global Metabolic Syndrome Market has been analysed by countries including the United States, Canada, United Kingdom, Germany, France, Italy, Spain, China, India and Japan.
• The key insights of the report have been presented through the frameworks of SWOT and Porter's Five Forces Analysis. Also, the attractiveness of the market has been presented by region, by Metabolic Syndrome Type, by Metabolic Syndrome Form, and by Sales Channel.
• Also, the major opportunities, trends, drivers and challenges of the industry have been analysed in the report.
• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Novo Nordisk, Eli Lilly and Company, Takeda Pharmaceutical, Sanofi, AstraZeneca, Amgen,Merck Co., Inc., Johnson & Johnson, Pfizer, and Abbott.
1. Market Background
1.1 Scope and Product Outlook
1.2 Executive Summary
1.3 Research Methodology
2. Strategic Recommendations
3. Global Metabolic Syndrome Market: Historic and Forecast (2018-2028)
3.1 Impact Analysis of Macro Economic Factors on Metabolic Syndrome Market
3.2 Impact of COVID-19 on Metabolic Syndrome Market
3.3 Global Metabolic Syndrome Market: Ecosystem Analysis
3.3.1 Metabolic Syndrome Fact Sheet
3.3.2 Pipeline Analysis of Metabolic Syndrome Therapeutics
3.3.3 Global Obesity Statistics 2022, in Millions
3.3.4 Top marketed Metabolic Syndrome Therapeutics by NPV, USDm
3.3.5 Top pipeline Metabolic Syndrome Therapeutics by NPV, in USD Millions
3.4 Global Metabolic Syndrome Market: Dashboard
3.5 Global Metabolic Syndrome Market: Market Value Assessment, 2018-2028 (USD Million)
3.6 Global Metabolic Syndrome Market Segmentation: By Indication
3.6.1 Global Metabolic Syndrome Market, By Indication Type Overview
3.6.2 Global Metabolic Syndrome Market Size, By Insulin Resistance Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
3.6.3 Global Metabolic Syndrome Market Size, By Hypercholesterolemia, By Value, 2018H-2028F (USD Million & CAGR)
3.6.4 Global Metabolic Syndrome Market Size, By Obesity Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
3.6.5 Global Metabolic Syndrome Market Size, By Nonalcoholic steatohepatitis, By Value, 2018H-2028F (USD Million & CAGR)
3.6.6 Global Metabolic Syndrome Market Size, By Other Indications, By Value, 2018H-2028F (USD Million & CAGR)
3.7 Global Metabolic Syndrome Market Segmentation: By Molecule Type
3.7.1 Global Metabolic Syndrome Market, By Molecule Type Overview
3.7.2 Global Metabolic Syndrome Market Size, By Small Molecule, By Value, 2018H-2028F (USD Million & CAGR)
3.7.3 Global Metabolic Syndrome Market Size, By Protein, By Value, 2018H-2028F (USD Million & CAGR)
3.7.4 Global Metabolic Syndrome Market Size, By RNA/DNA, By Value, 2018H-2028F (USD Million & CAGR)
3.7.5 Global Metabolic Syndrome Market Size, By Other Molecules, By Value, 2018H-2028F (USD Million & CAGR)
3.8 Global Metabolic Syndrome Market Segmentation: By Route of Administration
3.8.1 Global Metabolic Syndrome Market, By Route of Administration Overview
3.8.2 Global Metabolic Syndrome Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)
3.8.3 Global Metabolic Syndrome Market Size, By Subcutaneous, By Value, 2018H-2028F (USD Million & CAGR)
3.8.4 Global Metabolic Syndrome Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)
4. Global Metabolic Syndrome Market, Region Analysis
4.1 Regional Coverage of the Study
5. Americas Metabolic Syndrome Market: Historic and Forecast (2018-2028)
5.1 Americas Metabolic Syndrome Market: Snapshot
5.2 Americas Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
5.3 Americas Metabolic Syndrome Market: Key Factors
5.4 Americas Metabolic Syndrome Market Segmentation: By Indication
5.4.1 Americas Metabolic Syndrome Market, By Indication Overview
5.4.2 Americas Metabolic Syndrome Market Size, By Insulin Resistance Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
5.4.3 Americas Metabolic Syndrome Market Size, By Hypercholesterolemia, By Value, 2018H-2028F (USD Million & CAGR)
5.4.4 Americas Metabolic Syndrome Market Size, By Obesity Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
5.4.5 Americas Metabolic Syndrome Market Size, By Nonalcoholic steatohepatitis, By Value, 2018H-2028F (USD Million & CAGR)
5.4.6 Americas Metabolic Syndrome Market Size, By Other Indications, By Value, 2018H-2028F (USD Million & CAGR)
5.5 Americas Metabolic Syndrome Market Segmentation: By Molecule Type
5.5.1 Americas Metabolic Syndrome Market, By Molecule Type Overview
5.5.2 Americas Metabolic Syndrome Market Size, By Small Molecule, By Value, 2018H-2028F (USD Million & CAGR)
5.5.3 Americas Metabolic Syndrome Market Size, By Protein, By Value, 2018H-2028F (USD Million & CAGR)
5.5.4 Americas Metabolic Syndrome Market Size, By RNA/DNA, By Value, 2018H-2028F (USD Million & CAGR)
5.5.5 Americas Metabolic Syndrome Market Size, By Other Molecules, By Value, 2018H-2028F (USD Million & CAGR)
5.6 Americas Metabolic Syndrome Market Segmentation: By Route of Administration
5.6.1 Americas Metabolic Syndrome Market, By Route of Administration Overview
5.6.2 Americas Metabolic Syndrome Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)
5.6.3 Americas Metabolic Syndrome Market Size, By Subcutaneous, By Value, 2018H-2028F (USD Million & CAGR)
5.6.4 Americas Metabolic Syndrome Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)
5.7 Americas Metabolic Syndrome Market Segmentation: By Country
5.7.1 United States Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
5.7.1.1 United States Metabolic Syndrome Market, By Indication
5.7.1.2 United States Metabolic Syndrome Market, By Molecule Type
5.7.1.3 United States Metabolic Syndrome Market, By Route of Administration
5.7.2 Canada Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
5.7.2.1 Canada Metabolic Syndrome Market, By Indication
5.7.2.2 Canada Metabolic Syndrome Market, By Molecule Type
5.7.2.3 Canada Metabolic Syndrome Market, By Route of Administration
5.7.3 Rest of Americas Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
5.7.3.1 Rest of Americas Metabolic Syndrome Market, By Indication
5.7.3.2 Rest of Americas Metabolic Syndrome Market, By Molecule Type
5.7.3.3 Rest of Americas Metabolic Syndrome Market, By Route of Administration
6. Europe Metabolic Syndrome Market: Historic and Forecast (2018-2028)
6.1 Europe Metabolic Syndrome Market: Snapshot
6.2 Europe Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
6.3 Europe Metabolic Syndrome Market: Key Factors
6.4 Europe Metabolic Syndrome Market Segmentation: By Indication
6.4.1 Europe Metabolic Syndrome Market, By Indication Overview
6.4.2 Europe Metabolic Syndrome Market Size, By Insulin Resistance Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
6.4.3 Europe Metabolic Syndrome Market Size, By Hypercholesterolemia, By Value, 2018H-2028F (USD Million & CAGR)
6.4.4 Europe Metabolic Syndrome Market Size, By Obesity Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
6.4.5 Europe Metabolic Syndrome Market Size, By Nonalcoholic steatohepatitis, By Value, 2018H-2028F (USD Million & CAGR)
6.4.6 Europe Metabolic Syndrome Market Size, By Other Indications, By Value, 2018H-2028F (USD Million & CAGR)
6.5 Europe Metabolic Syndrome Market Segmentation: By Molecule Type
6.5.1 Europe Metabolic Syndrome Market, By Molecule Type Overview
6.5.2 Europe Metabolic Syndrome Market Size, By Small Molecule, By Value, 2018H-2028F (USD Million & CAGR)
6.5.3 Europe Metabolic Syndrome Market Size, By Protein, By Value, 2018H-2028F (USD Million & CAGR)
6.5.4 Europe Metabolic Syndrome Market Size, By RNA/DNA, By Value, 2018H-2028F (USD Million & CAGR)
6.5.5 Europe Metabolic Syndrome Market Size, By Other Molecules, By Value, 2018H-2028F (USD Million & CAGR)
6.6 Europe Metabolic Syndrome Market Segmentation: By Route of Administration
6.6.1 Europe Metabolic Syndrome Market, By Route of Administration Overview
6.6.2 Europe Metabolic Syndrome Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)
6.6.3 Europe Metabolic Syndrome Market Size, By Subcutaneous, By Value, 2018H-2028F (USD Million & CAGR)
6.6.4 Europe Metabolic Syndrome Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)
6.7 Europe Metabolic Syndrome Market Segmentation: By Country
6.7.1 France Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
6.7.1.1 France Metabolic Syndrome Market, By Indication
6.7.1.2 France Metabolic Syndrome Market, By Molecule Type
6.7.1.3 France Metabolic Syndrome Market, By Route of Administration
6.7.2 United Kingdom Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
6.7.2.1 United Kingdom Metabolic Syndrome Market, By Indication
6.7.2.2 United Kingdom Metabolic Syndrome Market, By Molecule Type
6.7.2.3 United Kingdom Metabolic Syndrome Market, By Route of Administration
6.7.3 Italy Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
6.7.3.1 Italy Metabolic Syndrome Market, By Indication
6.7.3.2 Italy Metabolic Syndrome Market, By Molecule Type
6.7.3.3 Italy Metabolic Syndrome Market, By Route of Administration
6.7.4 Spain Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
6.7.4.1 Spain Metabolic Syndrome Market, By Indication
6.7.4.2 Spain Metabolic Syndrome Market, By Molecule Type
6.7.4.3 Spain Metabolic Syndrome Market, By Route of Administration
6.7.5 Germany Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
6.7.5.1 Germany Metabolic Syndrome Market, By Indication
6.7.5.2 Germany Metabolic Syndrome Market, By Molecule Type
6.7.5.3 Germany Metabolic Syndrome Market, By Route of Administration
6.7.6 Rest of Europe Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
6.7.6.1 Rest of Europe Metabolic Syndrome Market, By Indication
6.7.6.2 Rest of Europe Metabolic Syndrome Market, By Molecule Type
6.7.6.3 Rest of Europe Metabolic Syndrome Market, By Route of Administration
7. Asia-Pacific Metabolic Syndrome Market: Historic and Forecast (2018-2028)
7.1 Asia-Pacific Metabolic Syndrome Market: Snapshot
7.2 Asia-Pacific Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
7.3 Asia-Pacific Metabolic Syndrome Market: Key Factors
7.4 Asia-Pacific Metabolic Syndrome Market Segmentation: By Indication
7.4.1 Asia-Pacific Metabolic Syndrome Market, By Indication Overview
7.4.2 Asia-Pacific Metabolic Syndrome Market Size, By Insulin Resistance Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
7.4.3 Asia-Pacific Metabolic Syndrome Market Size, By Hypercholesterolemia, By Value, 2018H-2028F (USD Million & CAGR)
7.4.4 Asia-Pacific Metabolic Syndrome Market Size, By Obesity Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
7.4.5 Asia-Pacific Metabolic Syndrome Market Size, By Nonalcoholic steatohepatitis, By Value, 2018H-2028F (USD Million & CAGR)
7.4.6 Asia-Pacific Metabolic Syndrome Market Size, By Other Indications, By Value, 2018H-2028F (USD Million & CAGR)
7.5 Asia-Pacific Metabolic Syndrome Market Segmentation: By Molecule Type
7.5.1 Asia-Pacific Metabolic Syndrome Market, By Molecule Type Overview
7.5.2 Asia-Pacific Metabolic Syndrome Market Size, By Small Molecule, By Value, 2018H-2028F (USD Million & CAGR)
7.5.3 Asia-Pacific Metabolic Syndrome Market Size, By Protein, By Value, 2018H-2028F (USD Million & CAGR)
7.5.4 Asia-Pacific Metabolic Syndrome Market Size, By RNA/DNA, By Value, 2018H-2028F (USD Million & CAGR)
7.5.5 Asia-Pacific Metabolic Syndrome Market Size, By Other Molecules, By Value, 2018H-2028F (USD Million & CAGR)
7.6 Asia-Pacific Metabolic Syndrome Market Segmentation: By Route of Administration
7.6.1 Asia-Pacific Metabolic Syndrome Market, By Route of Administration Overview
7.6.2 Asia-Pacific Metabolic Syndrome Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)
7.6.3 Asia-Pacific Metabolic Syndrome Market Size, By Subcutaneous, By Value, 2018H-2028F (USD Million & CAGR)
7.6.4 Asia-Pacific Metabolic Syndrome Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)
7.7 Asia-Pacific Metabolic Syndrome Market Segmentation: By Country
7.7.1 China Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
7.7.1.1 China Metabolic Syndrome Market, By Indication
7.7.1.2 China Metabolic Syndrome Market, By Molecule Type
7.7.1.3 China Metabolic Syndrome Market, By Route of Administration
7.7.2 Japan Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
7.7.2.1 Japan Metabolic Syndrome Market, By Indication
7.7.2.2 Japan Metabolic Syndrome Market, By Molecule Type
7.7.2.3 Japan Metabolic Syndrome Market, By Route of Administration
7.7.3 India Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
7.7.3.1 India Metabolic Syndrome Market, By Indication
7.7.3.2 India Metabolic Syndrome Market, By Molecule Type
7.7.3.3 India Metabolic Syndrome Market, By Route of Administration
7.7.4 Rest of Asia-Pacific Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
7.7.4.1 Rest of Asia-Pacific Metabolic Syndrome Market, By Indication
7.7.4.2 Rest of Asia-Pacific Metabolic Syndrome Market, By Molecule Type
7.7.4.3 Rest of Asia-Pacific Metabolic Syndrome Market, By Route of Administration
8. Middle-East & Africa Metabolic Syndrome Market: Historic and Forecast (2018-2028)
8.1 Middle-East & Africa Metabolic Syndrome Market: Snapshot
8.2 Middle-East & Africa Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
8.3 Middle-East & Africa Metabolic Syndrome Market: Key Factors
8.4 Middle-East & Africa Metabolic Syndrome Market Segmentation: By Indication
8.4.1 Middle-East & Africa Metabolic Syndrome Market, By Indication Overview
8.4.2 Middle-East & Africa Metabolic Syndrome Market Size, By Insulin Resistance Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
8.4.3 Middle-East & Africa Metabolic Syndrome Market Size, By Hypercholesterolemia, By Value, 2018H-2028F (USD Million & CAGR)
8.4.4 Middle-East & Africa Metabolic Syndrome Market Size, By Obesity Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
8.4.5 Middle-East & Africa Metabolic Syndrome Market Size, By Nonalcoholic steatohepatitis, By Value, 2018H-2028F (USD Million & CAGR)
8.4.6 Middle-East & Africa Metabolic Syndrome Market Size, By Other Indications, By Value, 2018H-2028F (USD Million & CAGR)
8.5 Middle-East & Africa Metabolic Syndrome Market Segmentation: By Indication
8.5.1 Middle-East & Africa Metabolic Syndrome Market, By Indication Overview
8.5.2 Middle-East & Africa Metabolic Syndrome Market Size, By Small Molecule, By Value, 2018H-2028F (USD Million & CAGR)
8.5.3 Middle-East & Africa Metabolic Syndrome Market Size, By Protein, By Value, 2018H-2028F (USD Million & CAGR)
8.5.4 Middle-East & Africa Metabolic Syndrome Market Size, By RNA/DNA, By Value, 2018H-2028F (USD Million & CAGR)
8.5.5 Middle-East & Africa Metabolic Syndrome Market Size, By Other Molecules, By Value, 2018H-2028F (USD Million & CAGR)
8.6 Middle-East & Africa Metabolic Syndrome Market Segmentation: By Route of Administration
8.6.1 Middle-East & Africa Metabolic Syndrome Market, By Route of Administration Overview
8.6.2 Middle-East & Africa Metabolic Syndrome Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)
8.6.3 Middle-East & Africa Metabolic Syndrome Market Size, By Subcutaneous, By Value, 2018H-2028F (USD Million & CAGR)
8.6.4 Middle-East & Africa Metabolic Syndrome Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)
9. Market Dynamics
9.1 Impact Assessment of Market Dynamics on the Global Metabolic Syndrome Market
9.2 Drivers
9.3 Restraints
9.4 Trends
10. Industry Ecosystem Analysis
10.1 Macro-Economic Factor Assessment
10.3 Porter's Five Forces Model
11. Competitive Positioning
11.1 Companies' Product Positioning
11.2 Market Position Matrix
11.3 Market Share Analysis of Metabolic Syndrome Market
11.4 Company Profiles
11.4.1 Novo Nordisk
11.4.2 Eli Lilly and Company
11.4.3 Takeda Pharmaceutical
11.4.4 Sanofi
11.4.5 AstraZeneca
11.4.6 Amgen
11.4.7 Merck Co., Inc.
11.4.8 Johnson & Johnson
11.4.9 Pfizer
11.4.10 Abbott